# US 2026/0265224 A1 · 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265224 A1
- Document ID: US20260265224A1
- Status: Published application
- Kind: A1
- Application number: 19/547,370
- Filed: 2026-02-23
- Published: 2026-09-10
- Earliest claimed: 2020-09-30
- Assignees: Agomab Spain, S.L.U.
- Applicants: Agomab Spain S.L.U.
- Inventors: Ramón BOSSER ARTAL; Begoña PAMPÍN CASAL; Julio CASTRO PALOMINO LARIA
- Web page: https://patentgrep.com/patent/US20260265224A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 11/06: Antiasthmatics
- C07D 413/14: containing three or more hetero rings
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as potent inhibitors of transforming growth factor-β receptor I, (also named activin receptor-like kinase 5) (TGFβRI)/ALK5. Other objectives of the present invention are to provide a procedure for preparing these compounds; pharmaceutical compositions comprising an effective amount of these compounds; the use of the compounds for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by inhibition of transforming growth factor-β receptor I (TGFβRI)/ALK5, such as respiratory diseases including idiopathic pulmonary fibrosis, asthma, COPD and lung cancer, and dermal and ocular fibrotic conditions.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A compound of formula (II):
wherein:
R1 represents a group selected from:
a) phenyl ring unsubstituted or substituted by 1 or 2 groups selected from halogen, linear or branched C1-C3 haloalkyl, linear or branched C1-C3 alkyl, linear or branched C1-C3 alkoxy, cyano and hydroxy,
b) 5- or 6-membered heteroaryl ring unsubstituted or substituted by 1 or 2 groups selected from halogen, linear or branched C1-C3 haloalkyl, linear or branched C1-C3 alkyl, linear or branched C1-C3 alkoxy, cyano and hydroxy,
R2 represents a group selected from:
a) hydrogen, and
b) linear or branched C1-C3 alkyl optionally substituted by 1, 2 or 3 halogen atoms,
R3 represents a group selected from:
a) hydrogen,
b) linear or branched C1-C3 alkyl optionally substituted by 1, 2 or 3 halogen atoms,
c) halogen, and
R4 and R5 independently represent a group selected from:
a) hydrogen,
b) linear or branched C1-C3 alkyl optionally substituted by 1, 2 or 3 halogen atoms, and
c) halogen atom,
or a salt thereof.

### Claim 25 (depends on 24)

The compound or a salt thereof according to claim 24, wherein R2 is hydrogen.

### Claim 26 (depends on 24)

The compound or a salt thereof according to claim 24, wherein R4 is hydrogen.

### Claim 27 (depends on 24)

The compound or a salt thereof according to claim 24, wherein R5 is hydrogen.

### Claim 28 (depends on 24)

The compound or a salt thereof according to claim 24, wherein R is methyl.

### Claim 29 (depends on 24)

The compound or a salt thereof according to claim 24, wherein R1 is phenyl substituted by 1 or 2 halogen atoms.

### Claim 30 (depends on 24)

The compound or a salt thereof according to claim 24, which is 3-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamido)-5-fluorobenzoic acid.

### Claim 31 (depends on 24)

The compound or a salt thereof according to claim 24, which is 5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamido)picolinic acid.

### Claim 32 (depends on 24)

The compound or a salt thereof according to claim 24, which is 6-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamido)pyridine-3-carboxylic acid.

### Claim 33 (depends on 24)

A process for the preparation of the compound of formula (II) or a salt thereof according to claim 24, which comprises reacting a compound of formula (IV):
or a salt thereof;
with a compound of formula (V):
or a salt thereof;
wherein R1, R2, R3, R4 and R5 are as defined in claim 24 and R9 is H or tBu.
